Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Citius Pharmaceuticals, Inc. (CTXR)

Citius: LYMPHIR wholesaler units rose 120% to 792 in fiscal fourth quarter

Positive Impact 3 of 5 earnings Written later

Citius Oncology, a majority-owned subsidiary of Citius Pharmaceuticals, reported preliminary, unaudited LYMPHIR unit sales for the fiscal fourth quarter ended September 30, 2026. Units purchased by U.S. wholesalers rose 120% from the prior quarter, and the number of institutions ordering the product grew, but the figures are unaudited and no revenue or profit amounts were disclosed, so the full financial picture will not be known until the annual report expected in December 2026.

Key points

  • 792 units purchased by U.S. wholesalers in the three months ended September 30, 2026, up 120% from 360 units in the three months ended June 30, 2026.
  • 950 LYMPHIR vials ordered by prescribing centers from wholesalers in the fiscal fourth quarter, compared with 926 in the fiscal third quarter.
  • 54 institutions had ordered LYMPHIR as of the release date, up from 44 as of August 14, 2026.
  • Figures are preliminary and unaudited; complete fiscal fourth quarter and fiscal 2026 results are expected in December 2026 with the Form 10-K.

The filing

CompanyCitius Pharmaceuticals, Inc. (CTXR)
Form8-K, current report
Filed with the SECOct 26, 2026, 4:05 PM ET
Accession number0001213900-26-112478

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.